Minapharm Pharmaceuticals results, Q4 2022
Net profit, assets, equity and cash flow for Q4 2022, against the same period a year earlier, from the published financial statements.
Net profit164 millionEGP · +43.7% vs the same period a year earlier
Total assets6.81 billionEGP · +65.8% vs the same period a year earlier
Shareholders' equity3.04 billionEGP · +56.5% vs the same period a year earlier
Operating cash flow195 millionEGP · +212.5% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q4 2022 was about 164 million EGP, up +43.7% from 114 million EGP in Q4 2021.
- Total assets at the end of Q4 2022 were about 6.81 billion EGP, and shareholders' equity about 3.04 billion EGP.
- Operating cash flow for Q4 2022 was positive at 195 million EGP.
Key lines against the same period a year earlier
This periodQ4 2021Change
Net profit164 million114 million+43.7%
Gross profit487 million337 million+44.4%
Total assets6.81 billion4.11 billion+65.8%
Total liabilities3.77 billion2.16 billion+74.1%
Shareholders' equity3.04 billion1.94 billion+56.5%
Total liabilities and equity6.81 billion4.11 billion+65.8%
Operating cash flow195 million62.52 million+212.5%
Investing cash flow-450 million-160 million−180.9%
Financing cash flow434 million39.03 million+1011.6%
Net change in cash179 million-58.63 million+405.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy